Grant Funding

  • National Institutes of Health (NIH). NIDDK Small Business Innovative Research (SBIR). 1R43DK103402-01A1. A novel biomaterial-based therapy to prevent type 1 diabetes. 09/15/2014 – 08/31/2015. G. Marshall (PI). Role: Founding Scientific Member for OneVax, LLC and UF sub-contract PI.

  • National Institutes of Health (NIH). NIDDK Human Islet Research Network (HIRN) UC4 grant (1UC4DK104194-01). Genetic Regulation of Human Beta Cell Destruction. 09/30/2014 – 06/30/2019. C. Mathews (PI/PD). Role: Project Co-Investigator.

  • The Leona M. and Harry B. Helmsley Charitable Trust. George S. Eisenbarth award for team science. 10/1/14-10/1/17. A. Pugliese (PI). Role: Co-Investigator.

  • Cord Blood Registry (CBR) Sponsored Non-restricted Research Grant.  Cord blood expansion of regulatory T cells.  Co-PIs – T.M. Brusko and MJ Haller (Peds).  01/19/2015-01/18/16. Role: Co-PI.

  • Hyundai Hope on Wheels. Sponsored Non-restricted Research Grant. Minimizing Leukemia Relapses: A Phase I Dose Escalation Study of Decitabine in High Risk. PI- Lamis Eldjerou (Peds). Role: Project Co-Investigator. 11/1/14-11/1/15.

  • University of Florida Preparatory Grant Program. Therapeutic targeting of immune metabolism. PI/PDs, Laurence Morel and Clayton Mathews. Role: Co-I and Immune Profiling Core PI. May 1, 2015-April 30, 2017.

  • American Diabetes Association (ADA). Minority Undergraduate Internship Funding Award (#1-16-MUI-02): Determining the influence of IL-12 and IL-18 signaling on Treg activity. 1/1/16-12/31/2016.  Role: Mentor PI.

  • National Institutes of Health. Human Islet Research Network (HIRN) Pilot Award. Characterization and in silico reconstruction of TCRs for modeling autoreactive T cells in T1D. NIH NIDDK 0U01DK104162-02. Sub-contract through the City of Hope 2/1/16-1/31/17. Joyce Nilan-PI, Role: UF PI.

  • National Institutes of Health. The CD226 and TIGIT costimulatory axis in type 1 diabetes. NIAID R01 (7/1/15-6/30/20). Role: PI

  • Cord Blood Registry (CBR) Sponsored Non-restricted Research Grant.  Clinical Trial Planning Grant for Treg Therapy in Type 1 Diabetes.  PI –MJ Haller (Peds).  06/29/2016-11/30/17. Role: Co-I.

  • National Institutes of Health. Insulin Specific T and B cells in Type 1 Diabetes. NIDDK DP3 1DP3DK110845-01 (08/01/2016-07/31/2019). PIs –J. Cambier and A. Michaels, Univ. of Colorado. Role: Co-I.

  • Univ of California San Francisco/National Institutes of Health/NIAID. 1P01AI118688 Disruption of T cell tolerance in type 1 diabetes. 06/06/2016-05/31/2019. Mark Anderson (PI) Role: Co-I

  • Juvenile Diabetes Foundation Research International (JDRF) Pilot and Feasibility Grant: The Influence of CD25 genotypes on the Control of CD25 and FOXP3 Expression.  Funding period 1-year. P.I. Mark Atkinson as addendum to Immunoregulatory Based Therapies for Type 1 Diabetes. 7-2006-328.

  • Juvenile Diabetes Foundation Research International (JDRF) Postdoctoral Fellowship. Engineered regulatory T cells as a means to restore tolerance in T1D. Funding period 2-years.

  • Juvenile Diabetes Foundation Research International (JDRF) Advanced Post-Doctoral Fellowship. Development of antigen-specific human Tregs for the treatment of T1D. Funding period 3-years with 1-year transition funding. Award 10-2010-191.

  • California Institute for Regenerative Medicine (CIRM). Tolerance induction using engineered stem cell-specific regulatory T cells. 3 Year funding period. Awarded as co-investigator under Jeffrey Bluestone-PI. (RM1-01703).

  • Juvenile Diabetes Foundation Research International (JDRF) Pilot and Feasibility Grant: Investigating human autoreactive T cell responses in humanized mice. Funding period 1-year (9/1/10-8/31/11). Role: P.I. under JDRF Center director Jeffrey A. Bluestone. Addendum to Collaborative Center for Cell Therapy (CCCT) grant 4-2005-1168

  • Juvenile Diabetes Foundation Research International (JDRF) Innovative Grant: Nanoparticle-coupled Tregs for the treatment of type 1 diabetes. Funding period 1-year (09/01/11-9/1/12). 5-2011-469. Role: P.I.

  • Juvenile Diabetes Foundation Research International (JDRF) Award 25-2010-702. Post-transcriptional regulation of pancreas-targeting nTreg cells. PI-Manuela Battaglia, Institute San Rafaelle. Milan, Italy. June 30, 2010-June 30th, 2013. Role: Sub-contracted Co-investigator.

  • Juvenile Diabetes Foundation Research International (JDRF). Autoimmunity Center Consortium (ACC) Cord Blood Center Grant, Project 1 Cord Blood Therapies for Type 1 Diabetes. JDRF 4-2007-1065.  PI-Mark Atkinson. Aug 1, 2011-Aug 1, 2012. Role: Co-investigator.

  • Juvenile Diabetes Foundation Research International (JDRF). Career Development Award. Investigating human autoreactive T cells in humanized mice. JDRF 2-2012-280. 5/1/12-5/1/16. Role: P.I.

  • American Diabetes Association (ADA). Innovative Grant: Role of T cell mitochondrial function in type 1 diabetes. 7/1/12-6/30/14. Role: Co-investigator.

  • Juvenile Diabetes Foundation Research International (JDRF). Pioneering pilot grant: Lymphocyte mitochondrial dysfunction on type 1 diabetes. JDRF 17-2012-595. PI – Jing Chen. 09/01/2012-08/31/2015. Role: Co-Investigator.

  • National Institutes of Health (NIH). R01-AI045050. Characterization of SLE-susceptibility loci on mouse chromosome 1. PI – Laurence Morel. 05/01/2013-04/30/2018. Role: Co-Investigator.

  • Alliance for Lupus Research (ALR). CD4 T cell metabolism in SLE: Characterization and target identification. Feb 1, 2013-Jan 31, 2016. PI – Laurence Morel. Role Co-Investigator.

  • PerkinElmer Sponsored Non-restricted Research Grant.  Autologous umbilical cord blood expanded regulatory T cell therapy in children with type 1 diabetes.  Co-PIs – T.M. Brusko and MJ Haller (Peds).  06/2013-06/2014.  Role: Co-PI.

  • UF Sponsored Seed Grant. Mucosal Therapeutics for Type 1 Diabetes. PI – David Pascual (Veterinary Medicine). 5/1/2013-4/30/2015. Role: Co-I.

  • National Institutes of Health (NIH). P01. Immune function and the progression to type 1 diabetes. PI – Mark A. Atkinson. 05/01/2013-04/30/2018. Role: Co-Investigator for Project 2. 

  • Pfizer – Inspire Hemophilia Grant. Regulatory T Cells with Chimeric Antigen Receptor for Immune Tolerance to Factor VIII. 10/1/13-9/30/15. Role: PI

  • American Diabetes Association (ADA). Basic Science Award (#7-13-BS-022): Influence of IL-12 and IL-18 on immunoregulation and type 1 diabetes pathogenesis. 7/1/13-6/30/16. Role: PI.

  • National Institutes of Health (NIH). Small Business Innovative Research (SBIR) grant. 1R43DK100132-01. Polymeric biomaterial-based microparticle vaccine for amelioration of type 1 diabetes. 9/15/2013-8/31/2014. Role: Founding Scientific Member for OneVax, LLC.

  • Diabetes Research Connection. Nanoparticle coupled regulatory T cells for the treatment of type 1 diabetes. Pilot and feasibility grant mechanism; approved, pending funding. Role: PI.